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Faecal microbiota transplantation (FMT) has been reported to be effective in
treating relapsing of refractory Clostridium difﬁcile infections, although some practical
barriers are limiting its widespread use. In this study, our objective was to evaluate the
rate of resolution of diarrhea following administration of lyophilized and resolved
FMT via a nasogastric (NG) tube. We recruited 19 patients suffered from laboratory-
conﬁrmed C. difﬁcile infection. Each of them was treated by lyophilized and resolved
inoculum through a NG tube. One participant succumbed following the procedure due
to unrelated diseases. Out of 18 cases, 15 patients reportedly experienced a resolution
of the symptoms. One patient was treated with another course of antibiotics, and two
of the non-responders were successfully retreated with another course of FMT
utilizing a lyophilized inoculum. Notably, no signiﬁcant adverse activities were
observed. In accordance to our clinical experiences, a patient will likely beneﬁt from
FMT treatment including lyophilized inoculum.
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Introduction
Clostridium difﬁcile is a Gram-positive, obligate anaerobic, spore-forming
bacterium. It was ﬁrst described as a member of commensal ﬂora in 1935;
however, since the late 70s, it has been recognized as the most important causative
agent of antibiotic-associated diarrhea and pseudomembraneous colitis [1, 2]. In
recent years, C. difﬁcile infection (CDI) has become a major clinical entity [3–5].
Due to a hypervirulent strain (NAP1/BI/021), which emerged in the early 2000s,
CDI tends to be less responsive to conventional therapy and both of the proportion
of recurrent and severe episodes have risen [6, 7]. Recently published papers
suggest that faecal microbiota transplantation (FMT) could be a reasonable option
among these clinical circumstances [8–12]. Compared with many other medical
procedures, FMT is not complicated and is considered cost-effective. Most of the
clinicians are performing FMT using freshly prepared samples, which has a
limited viability, usually estimated up to 6 h. Furthermore, proper donor screening
is a long procedure precluding the use of FMT in acute cases. These logistical
barriers of the procedure inspire clinicians to investigate the possibility of the use
of pooled, standardized samples. According to the published data of Hamilton
et al. [13], the use of frozen and thawed FMT was not found inferior when
compared with the use of fresh FMT, and this data were conﬁrmed in a paper
written by Lee et al. [14]. In this study, our aim was to evaluate the possibility of
the use of lyophilized specimen for FMT.
Methods
Patient indications
In this study, participants were recruited from the patients referred to the
Infectious Diseases Ward of the 1st Department of Internal Medicine of
University of Pécs. Subjects with refractory or recurrent active CDI were
included. Active CDI was deﬁned as a diarrhea (>3 loose stools per day)
including a positive stool test result of C. difﬁcile toxin enzyme-linked immu-
nosorbent assay. A recurrent episode was deﬁned as the presence of diarrhea and
a positive C. difﬁcile stool assay within 2–6 weeks from the initial episode.
Refractory CDI was deﬁned as failure of a 2-week vancomycin therapy with or
without an alternative antibiotic. Major exclusion criteria included acute abdo-
men, signs of perforation, recent operation with the opening of the upper or
lower gastrointestinal (GI) tract, upper GI tract hemorrhage, signs of ileus, and
uncontrollable vomiting.
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Donor determination and screening
Our donors were healthy, non-pregnant adults. In our clinical practice, each
of our donors served as a volunteer. It is immediately clear that proper donor
screening is essential to avert the likely transmission of communicable diseases.
Our essential strategy included an oral interview and a physical examination of the
donor in the screening process. Many authors recommend using a simple
questionnaire (e.g., FDA Full-Length Donor History Questionnaire [15]) for
identifying potential risk factors considered undetectable in the laboratory. We
used this questionnaire and adapted it to the local circumstances. Individuals with
any signiﬁcant medical history, for use of any antibiotics, or with a history of any
extensive travel in the preceding 6 months, drug abusers, and individuals with
high-risk sexual behavior were excluded. Recently published papers suggest that
the intestinal microbiota plays a very important role in many chronic diseases,
such as Crohn’s disease and ulcerative colitis, metabolic syndrome, cancer,
obesity [16], and irritable bowel syndrome [17]. The exclusion of donors with
any evidence of autoimmune or other chronic conditions should be considered,
until the exact role of the intestinal microbiota in these conditions is substantiated
in reference to the donors.
Volunteers underwent a physical examination and general laboratory
screening tests. Donated faeces were screened for parasites, enteropathogenic
bacteria, and C. difﬁcile, whereas the serum was screened for HIV-1 and
HIV-2, EBV, CMV, hepatitis A, B, and C viruses and Treponema pallidum.
Preparation of the sample
However, there are no evidence based-recommendations of FMT; meta-
analysis suggests that a larger volume of faeces will increase the success rate and
reduce the relapse rate [18–20]. Most authors recommend the use of normal saline,
but some have used milk in view of the ﬁnding that patients with recurrent CDI
excrete lower amounts of short-chain fatty acids into their faeces as compared with
healthy controls [21, 22].
The donated faeces were transported to our department within 2 h of passage.
A 60-g sample was homogenized in a mortar and suspended in 200 ml of normal
saline (0.9%). The suspension was then ﬁltered through 4 × 4 cm sheets of sterile
gauze into another container, and 100 ml of the ﬁltrate was acquired in a sterile
container. All of the steps of the preparation were performed in a laminated ﬂow
box and sterile devices were used. Next, the ﬁltrate was frozen at −20 °C for 24 h
in a thin layer, and over a large surface area within a plastic container. Following
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all the above, it was then lyophilized with a Heto Drywinner Freeze Dryer, Biolab
Inc. in −40 °C, under vacuum. The lyophilized transplant material (TM) was stored
for a maximum of 8 weeks at normal temperature (21 °C). Prior to the FMT
procedure, the lyophilized material was dissolved in 100 ml of sterile distilled water.
Recipient preparation
Generally, if and when the condition of the patient permitted, discontinua-
tion of antibiotics 4 days prior to the procedure was required. Participants were
asked to fast 8 h prior and 3 h following the FMT. In serious cases, this period was
reduced to 1 day. In each case, thorough purging was applied on the day prior to
the intervention, to effectively increase the success of the procedure, by ﬂushing
away residual faeces, antibiotics, toxins, C. difﬁcile bacteria, and spores to the
maximum attainable extent. The patients received a double dose of proton pump
inhibitor intravenously in the morning of the planned procedure. This increases the
chance of survival of the transplanted ﬂora by reducing the gastric acid output.
About 1 h prior to the transplantation, 20 mg ofmetoclopramidewas intravenously
administered, to prevent vomiting and to facilitate bowel movement to promote
the delivery of the transplantation material to the colon.
FMT delivery
In accordance with recently published results [10, 23–26], our experiences
revealed that FMT via upper GI tract is also a highly effective procedure [27]. NG
tubes were inserted prior to the procedure including 100 ml of solution, which was
ﬂushed in. During upper GI tract delivery all of the patients were set in a semi-
sitting position throughout the procedure and 1 h afterward. Next, the patients
were encouraged to resume both normal diets and physical activities.
Cure rate
Primary cure rate is deﬁned as the percentage of cases in which the
symptoms are considered resolved without recurrence within 6 weeks following
the FMT, and the secondary cure rate as the percentage of cases in which
the symptoms are resolved following a second FMT [28]. IDSA/SHEA guide-
lines do not recommend C. difﬁcile testing in patients who do not have
symptoms, because patients can be colonized with C. difﬁcile and do not
develop the disease [29, 30].
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All of our patients were hospitalized and discharged three or more days
following FMT. Possible adverse events were elicited by the medical staff of our
ward, based on a self-report of the patients. Fever, GI symptoms, headache,
fatigue, and rash were the main symptoms evaluated.
Results
Table I summarizes the demographic characteristics and clinical outcomes
of the 19 participants. Between August 2013 and June 2015, we performed FMT
with lyophilized TM on a total of 19 patients, of whom nine (47.36%) were
females. The mean age was 67.73 years, with a range of 38–94 years. In all
cases, the diagnosis of C. difﬁcile colitis had been conﬁrmed by positive stool test
results for C. difﬁcile toxin. The average number of recurrent infections was 2.0
Table I. Demographic characteristics of and clinical outcomes for patients
Patient
Age
(years) Sex
C. difﬁcile
test results
before FMT
Severe
episode of
CDI at
FMT
Recurrent
episodes of
CDI before
FMT
Clinical
outcome
after ﬁrst
FMT
Clinical
outcome
after
second
FMT
1 75 F Positive Yes 4 Resolution NA
2 38 F Positive Yes 3 Treatment
failure
Resolution
3 94 F Positive Yes 0 Resolution NA
4 82 M Positive Yes 1 Resolution NA
5 65 M Positive Yes 2 Resolution NA
6 51 M Positive Yes 1 Resolution NA
7 75 M Positive No 3 Death NA
8 67 F Positive No 1 Resolution NA
9 62 M Positive Yes 2 Resolution NA
10 70 F Positive Yes 0 Resolution NA
11 79 M Positive Yes 4 Resolution NA
12 62 M Positive Yes 4 Resolution NA
13 85 M Positive Yes 1 Resolution NA
14 70 M Positive Yes 5 Resolution NA
15 58 F Positive Yes 2 Resolution NA
16 57 F Positive Yes 0 Treatment
failure
Resolution
17 67 F Positive Yes 2 Resolution NA
18 73 F Positive No 1 Treatment
failure
NA
19 57 M Positive Yes 2 Resolution NA
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(range: 0–5). All of the patients had received at least one course of metronidazole/
vancomycin. These treatments had been provided by the medical staff within our
ward. In three cases, FMT was carried out to treat the ﬁrst episode of FMT,
because of the severity of the infection and the failure of preceding antibiotic
treatment. In 16 cases (84.21%), the patients had severe CDI during the trans-
plantation. All participants were admitted at least 1 day prior, and were hospital-
ized for at least three additional days following the procedure.
Patient 7 suffering from severe comorbidity (chronic obstructive pulmonary
disease and polyvascular disease) and who was in a very poor general condition
succumbed 2 days following the procedure. Among the surviving 18 patients,
15 (83.33%) reported having a normal stool within 48 h following the FMT. Three
patients proved to be non-responders. Patients 2 and 16 underwent a second
transplantation, and following a second treatment, the clinical resolution of the
diarrhea was reported in both cases. Patient 18 developed diarrhea within 5 days
following the stool transplantation, and additional stool tests for C. difﬁcile toxin
was found to be positive. She was treated by an additional course of ﬁdaxomicin
and clinical resolution of her symptoms was reported within 4 days.
We experienced in which FMT through NG tubes, using a freeze-dried
specimen, has the primary cure of 83.33%, whereas the secondary cure rate was
found to be 100%.
No serious adverse events or recurrences were observed. None of the
patients reported vomiting within 24 h of administration. Mild adverse events,
e.g., bloating, abdominal cramps, and nausea, were reported only in three cases
(16.67%).
Discussion
Today, C. difﬁcile is a cause of antibiotic-associated diarrhea and pseudo-
membranous colitis. The severity of the disease ranges from mild cases, where
discontinuation of antimicrobials and supportive care could be efﬁcient, to severe
life-threatening cases. It has a relevant impact of morbidity and mortality in the
elderly. Recommended therapies for CDI include oral administration of metronida-
zole or vancomycin. Reported data suggest that antibiotic treatment has a clinical
efﬁciency >90%. Recurrent episodes of CDI are generally treated with an additional
course of metronidazole or vancomycin. However, some patients develop a chronic
pattern of recurrent CDI. Limited experience with FMT in Europe and the United
States suggests it may likely be the solution in treating these individuals.
Our former clinical experiences demonstrated FMT via the upper GI tract,
using freshly prepared suspension, is indeed an effective procedure to treat CDI. In
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the implementation of our treatment, the overall primary cure rate of upper GI tract
FMT is reportedly 82.43%, whereas the overall secondary cure rate was 94.59%
[27]. During this study, we experienced the same efﬁciency. These results are not
inferior to those which have been reported in meta-analytical studies [18, 19]. We
prefer to use NG tubes in our practice, largely due to the advantage in which it
requires less patient preparation, clinical time, less patient inconvenience, and
considerably inexpensive when compared with other routes of administration.
This method does not require the specialized skills of endoscopic procedures and it
can be performed at the patients’ bedside. However, it is important to note that this
method has several limitations. The most important concerns are the limited
viability of the samples and the long screening procedure of the donors on each
occasion. Moreover, many of our patients are elderly without any healthy living
relatives. These facts inspired us to investigate an alternative method for FMT.
According to the recorded data of Hamilton et al., which were conﬁrmed by Lee
et al., the use of frozen samples is as effective as the use of freshly prepared
suspension. This method requires a refrigerator to store the specimen. The papers
published by Kupletskaya [31] and Antheunisse [32] suggest that bacteria can
retain their viability after a freeze-drying (lyophilization) procedure. This data
inspired us to investigate the possibility and effectiveness of this procedure.
Although we experienced an excellent clinical outcome, it is important to
note that this study has major limitations, such as the small sample size and the
lack of placebo or active comparator. The design of a multicenter study involving
larger numbers of patients and with active comparators should be considered in the
future. If our data are to be reproduced, it will likely serve toward making FMT
accessible to a wider population of patients. In addition, encapsulating the freeze-
dried specimen may very well prove to be a promising future prospect. The other
major limitation is the problem of long-term follow up. All study participants were
contacted by phone, both 6 weeks and 6 months following the FMT. They were
asked to complete a short questionnaire concerning their bowel movements,
abdominal pain, and general well-being, recurrent episode of CDI, antibiotic
intake since FMT, and any new medical conditions occurring since receiving
FMT. No new medical conditions were reported. However, it is important to note
that these answers were not conﬁrmed by a health care professional (e.g., a general
practitioner or a nurse), and no control stool tests were done.
Conclusions
Despite deﬁciencies in the design of this study, our results seem to
adequately support that FMT, using a lyophilized material through NG tube
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administration, is a rational treatment option for patients with recurrent or
refractory CDI. Controlled trials need to be done to further prove the
effectiveness of this method, and to determine the ideal procedure in which
to treat recurrent or antibiotic refractory CDI in the most effective measure
possible.
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